Most contract research organisations do one thing well. They run assays, or they synthesise compounds, or they manufacture API. Aragen Life Sciences, based in Hyderabad with twenty-four years of continuous operation, does all three — and connects them into a single, integrated service that takes a client’s molecule from the earliest stages of discovery through commercial-scale manufacturing. In an industry that fragments work across a dozen vendors, that continuity is the product.
The pharmaceutical outsourcing industry has a vocabulary problem. CROs do research. CDMOs do manufacturing. CMOs do production. The acronyms multiply, and the boundaries between them remain fuzzy because, in practice, a drug molecule does not care which department handles it. It needs to move from a hit in a screening assay to a scaled-up, regulatory-compliant manufacturing process — and every handoff between vendors introduces delay, information loss, and risk.
Aragen’s answer to this problem is to eliminate the handoffs. The company operates as a CRDMO — Contract Research, Development, and Manufacturing Organisation — offering integrated services across the entire drug development value chain. A client can engage Aragen at the discovery stage, where medicinal chemists design and synthesise candidate molecules, and stay with the same organisation through process development, analytical method validation, GMP manufacturing, and commercial supply.
This is not a trivial thing to build. It requires investment in discovery-stage capabilities (biology, pharmacology, in-vivo studies) alongside heavy-industry assets (reactors, distillation columns, API manufacturing suites). Most companies pick one end of the spectrum. Aragen chose both, and has spent two decades assembling the people and infrastructure to make the model work.
Aragen’s service offering spans four interconnected domains, each staffed with dedicated scientific teams and supported by purpose-built facilities in Hyderabad and Visakhapatnam.
Aragen does not make headlines. It does not sell branded medicines in pharmacies. Its name does not appear on prescription labels. But behind the scenes, its scientists and engineers have contributed to drug development programmes for some of the world’s largest pharmaceutical and biotechnology companies. The work is confidential by nature — a client’s proprietary molecule is treated with the same discretion as a trade secret — which means that Aragen’s contributions to global health are largely invisible to the public.
This invisibility is, in a sense, the point. A CRDMO succeeds when its clients succeed. When a drug reaches patients, the contract research organisation that helped develop the synthesis route and manufactured the clinical trial material rarely gets mentioned. Aragen has built a business on being essential but unnamed — the kind of company that global pharma cannot do without but that most people have never heard of.
Aragen’s revenue growth tells a story of steady expansion punctuated by the normal fluctuations of project-based work. From $168 million in FY22 to $222 million in FY25, the company has grown at a compound rate that outpaces the broader Indian CDMO sector. The slight dip in FY24 — to $201 million from $210 million — reflected the timing of project completions and new contract ramp-ups, not a structural issue. FY25’s rebound to $222 million, accompanied by an expansion of the workforce to 4,500, suggests the order book is healthy.
The company has also been investing in capacity. New manufacturing blocks, expanded laboratory space, and additional analytical instrumentation have been added in recent years — all aimed at handling larger and more complex programmes as global pharma companies consolidate their outsourcing relationships with fewer, more capable partners.
Hyderabad is to Indian pharmaceutical services what Bangalore is to IT: a city that has built an ecosystem. The concentration of chemistry and biology talent in the region — fed by institutions like the Indian Institute of Chemical Technology, Osmania University, and the University of Hyderabad — gives companies like Aragen access to a deep pool of trained scientists at every career stage.
But talent alone does not explain the city’s dominance. Hyderabad also offers something more practical: a cost structure that allows a mid-sized CRDMO to invest in capabilities that would be prohibitively expensive in Boston or Basel. A medicinal chemistry team in Hyderabad can run the same assays, use the same instruments, and publish in the same journals as their counterparts in Cambridge, Massachusetts — at a fraction of the operating cost. This is not about cutting corners. It is about the economics of geography, and Aragen has leveraged that advantage for twenty-four years.
Sources: Aragen Life Sciences Annual Reports FY2021–22 through FY2024–25. US FDA facility registration data.